查看購物車
  • Simplified Chinese
  • English
  • Japanese
散瞳市場 - 全球和區域分析 - 分析和預測（2025-2035）
市場調查報告書
商品編碼
1759272

散瞳市場 - 全球和區域分析 - 分析和預測（2025-2035）

Mydriasis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

散瞳是醫學術語，指瞳孔擴張，即瞳孔變得異常大。

這種症狀可能是在低光源環境下自然發生的（以便讓更多光線進入眼睛），也可能是醫學原因引起的。瞳孔擴張通常在眼科檢查中被有意使用，以便更清晰地觀察視網膜、視神經和眼內其他結構。它在診斷各種眼科疾病至關重要，包括青光眼、糖尿病視網膜病變和老齡化黃斑部病變(AMD)。

散瞳症可以透過使用托吡卡胺、苯腎上腺素或阿托品等散瞳藥物來誘發，這些藥物可以放鬆瞳孔周圍的肌肉，使瞳孔擴張。雖然散瞳症通常是一種暫時性疾病，但神經系統疾病、眼外傷以及某些藥物的作用也可能引起散瞳症。

散瞳市場的主要驅動力之一是對先進眼科診斷技術日益成長的需求。隨著眼底攝影機、光同調斷層掃瞄(OCT) 和視網膜影像處理系統等醫學影像系統的不斷改進，精確的瞳孔擴張對於最佳性能至關重要。

這些技術可以提供視網膜、視神經和其他重要眼內結構的高解析度影像，這些影像對於診斷青光眼、糖尿病視網膜病變和黃斑部病變等各種眼科疾病至關重要。在這種診斷中，散瞳對於獲得清晰準確的影像至關重要，因此增加了對引起瞳孔擴張的散瞳藥物的需求。隨著這些診斷工具變得越來越普及和高效，對散瞳藥物的需求持續成長，大大促進了散瞳藥物市場的擴張。此外，慢性眼科疾病率的上升和全球人口老化進一步刺激了常規眼科檢查中對瞳孔擴張的需求，使散瞳成為現代眼部保健的重要組成部分。

儘管散瞳劑市場正在成長，但仍有許多挑戰阻礙其發展。其中最主要的挑戰之一是散瞳劑的副作用和安全隱患。雖然這些藥物可以有效地擴張瞳孔用於診斷，但它們可能導致眼部不適、眼壓升高、畏光（對光敏感）和視力模糊。在某些情況下，它們還可能引起全身副作用，例如心率加快和高血壓，尤其對於患有高血壓或心血管疾病等潛在疾病的人。

此外，過度擴張的風險可能會使診斷過程複雜化，或在後續治療中引起副作用。有些患者，尤其是老年人、糖尿病患者或青光眼患者，擴張過程可能有困難，可能需要額外的監測或調整。

此類安全隱患可能會限制散瞳劑的廣泛使用，尤其是在脆弱的患者群體中，並減緩某些散瞳療法的普及。這項挑戰凸顯了對更安全、更有效的替代方案的需求，這些方案既能達到診斷操作所需的瞳孔擴大程度，又能最大限度地減少副作用。

全球散瞳藥市場競爭激烈，多家主要企業推動創新和市場成長。 Viatris Inc.、Opus Genetics、Eyenovia, Inc.、Rayner Surgical Group Limited、Omeros Corporation、愛爾康公司、諾華公司、輝瑞公司、Akorn, Inc. 和艾伯維公司等公司處於散瞳藥技術進步和研發的前沿，以滿足日益成長的眼科診斷需求。

這些公司在研發方面投入巨資，致力於提升散瞳藥物治療的療效、安全性和病患體驗。此外，策略合作夥伴關係、收購和產品系列擴展使這些公司保持了競爭力並提升了市場佔有率。隨著眼底攝影機和光同調斷層掃瞄(OCT) 等眼科成像技術的不斷發展，這些公司將在塑造全球散瞳藥物市場的未來方面發揮關鍵作用。

市場區隔

細分一：按地區

    • 北美洲
    • 歐洲
    • 亞太地區

全球散瞳市場正經歷重大變革時期，其驅動力源自於重塑眼科診斷格局的幾個關鍵因素。首先，眼底攝影機和光同調斷層掃瞄(OCT) 等影像技術的快速發展，正在徹底改變眼科醫師檢查視網膜和視神經的方式。這些技術需要精確的瞳孔擴張才能捕捉高解析度、精細的影像，從而推動了對有效散瞳劑的需求。

其次，青光眼、糖尿病視網膜病變和白內障等慢性眼科疾病疾病的發生率不斷上升，顯著增加了定期進行瞳孔擴張診斷程序的需求。隨著世界人口老化，尤其在已開發國家，對這些疾病的早期發現和管理的需求日益增加，以防止永久性視力喪失。

此外，新興市場醫療保健服務的擴大也進一步推動了市場的成長，尤其是在亞太地區和拉丁美洲等地區，這些地區獲取現代診斷工具的機會增加，導致接受需要散瞳眼科檢查的患者數量增加。

最後，眼科領域對個人化醫療和精準診斷的日益重視，推動了散瞳治療的創新。各公司正在開發更安全、起效更快的散瞳解決方案，以滿足個別患者的需求，從而實現更有效率、更舒適的眼科檢查。所有這些因素都推動著散瞳市場的持續轉型，使其成為全球醫療保健領域中一個充滿活力且快速變化的領域。

本報告研究了全球散瞳症市場，並提供了市場概述以及區域趨勢和公司概況。

目錄

執行摘要

第1章 全球散瞳市場：產業展望

  • 介紹
  • 市場趨勢
  • 法律規範
  • 流行病學分析
  • 臨床試驗分析
  • 市場動態

2. 2023 年至 2035 年全球散瞳症市場（按地區）

  • 北美洲
  • 歐洲
  • 亞太地區

第3章全球散瞳藥市場：競爭格局與公司概況

  • 關鍵策略和發展
    • 合併與收購
    • 協同活動
    • 業務擴展和資金籌措
    • 產品發布和核准
    • 其他活動
  • 公司簡介
    • Viatris Inc.
    • Opus Genetics
    • Eyenovia, Inc.
    • Rayner Surgical Group Limited
    • Omeros Corporation
    • Alcon Inc.
    • Novartis AG
    • Pfizer Inc.
    • Akorn, Inc.
    • AbbVie Inc.

第4章調查方法

Product Code: BHL3067SA

Global Mydriasis Market, Analysis and Forecast: 2025-2035

Mydriasis is a medical term that refers to the dilation of the pupil, where the pupil becomes abnormally enlarged. This condition can occur naturally in response to low light conditions (to allow more light into the eye) or can be induced for medical reasons. Mydriasis is often used intentionally in ophthalmology during eye exams to provide a clearer view of the retina, optic nerve, and other structures inside the eye. It is essential for the diagnosis of various eye conditions, including glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD).

Mydriasis can be induced using mydriatic agents, such as tropicamide, phenylephrine, or atropine, which relax the muscles around the pupil, causing it to dilate. While it is typically a temporary condition, mydriasis can also occur due to neurological disorders, eye trauma, or the effects of certain medications.

One of the key drivers of the mydriasis market is the growing demand for advanced ophthalmic diagnostic technologies. As medical imaging systems like fundus cameras, optical coherence tomography (OCT), and retinal imaging systems continue to improve, they require precise pupil dilation for optimal performance.

These technologies provide high-resolution images of the retina, optic nerve, and other critical structures inside the eye, which are essential for diagnosing a variety of eye diseases such as glaucoma, diabetic retinopathy, and macular degeneration. Mydriasis is crucial for obtaining clear, accurate images during these diagnostic procedures, which is driving the increased demand for mydriatic agents that induce pupil dilation. As these diagnostic tools become more widespread and more efficient, the need for mydriatic drugs continues to grow, significantly contributing to the expansion of the mydriasis market. Additionally, the rising prevalence of chronic eye conditions and the aging global population further fuel the demand for pupil dilation in routine eye exams, making mydriasis a critical component of modern ophthalmic care.

Despite the growth of the Mydriasis market, several challenges continue to hinder its progress. One of the primary challenges is the side effects and safety concerns associated with mydriatic agents. While these agents are effective in inducing pupil dilation for diagnostic purposes, they can cause ocular discomfort, increased intraocular pressure, photophobia (sensitivity to light), and blurred vision. In some cases, they may also cause systemic side effects, such as increased heart rate or high blood pressure, particularly in individuals with underlying health conditions like hypertension or cardiovascular diseases.

Additionally, there is a risk of over-dilation, which can complicate the diagnostic process or lead to adverse effects during subsequent treatment. Some patients, especially the elderly or those with diabetes or glaucoma, may experience difficulty with the dilation process, potentially requiring additional monitoring or adjustments.

These safety concerns limit the widespread use of mydriatic agents, especially in vulnerable patient populations, and may slow the adoption of certain types of mydriatic treatments. This challenge underscores the need for safer, more effective alternatives that can minimize side effects while still achieving the necessary level of pupil dilation for diagnostic procedures.

The global Mydriasis market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Viatris Inc., Opus Genetics, Eyenovia, Inc., Rayner Surgical Group Limited, Omeros Corporation, Alcon Inc., Novartis AG, Pfizer Inc., Akorn, Inc., and AbbVie Inc. are at the forefront of advancing technologies and developing mydriatic agents to address the growing demand for ophthalmic diagnostics.

These companies are investing heavily in research and development (R&D), focusing on improving the efficacy, safety, and patient experience of mydriatic treatments. Furthermore, strategic partnerships, acquisitions, and expanding product portfolios are helping these companies maintain a competitive edge and expand their market presence. As ophthalmic imaging technologies like fundus cameras and optical coherence tomography (OCT) continue to evolve, these companies are poised to play a crucial role in shaping the future of mydriasis in the global market.

Market Segmentation:

Segmentation 1: by Region

    • North America
    • Europe
    • Asia-Pacific

The global Mydriasis market is undergoing significant transformation, fuelled by several key factors that are reshaping the landscape of ophthalmic diagnostics. First, the rapid advancements in imaging technologies such as fundus cameras and optical coherence tomography (OCT) are revolutionizing the way ophthalmologists examine the retina and optic nerve. These technologies require precise pupil dilation to capture high-resolution, detailed images, driving the demand for effective mydriatic agents.

Second, the rising prevalence of chronic eye conditions, including glaucoma, diabetic retinopathy, and cataracts, is significantly increasing the need for regular diagnostic procedures involving mydriasis. As the global population ages, particularly in developed countries, there is a greater need for early detection and management of these conditions to prevent permanent vision loss.

Moreover, the expansion of healthcare access in emerging markets is further accelerating market growth. As access to modern diagnostic tools improves, particularly in regions such as Asia-Pacific and Latin America, more patients are undergoing eye exams that require pupil dilation.

Finally, the growing emphasis on personalized medicine and precision diagnostics in ophthalmology is driving innovation in mydriasis treatments. Companies are developing safer, faster acting mydriatic agents tailored to individual patient needs, ensuring more efficient and comfortable eye exams. These factors are all contributing to the ongoing transformation of the mydriasis market, making it a dynamic and fast-evolving sector in the global healthcare landscape.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Mydriasis Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Mydriasis Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Mydriasis Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Mydriasis Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Mydriasis Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Mydriasis Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Viatris Inc.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Opus Genetics
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Eyenovia, Inc.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Rayner Surgical Group Limited
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Omeros Corporation
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Alcon Inc.
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Novartis AG
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Pfizer Inc.
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Akorn, Inc.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 AbbVie Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Mydriasis Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Mydriasis Market Key Trends, Analysis

List of Tables

  • Table: Global Mydriasis Market Dynamics, Impact Analysis
  • Table: Global Mydriasis Market (by Region), $Billion, 2024-2035